Associated tags: FDA, Water purification, Dialysis, Patient, Health, Medical Devices, Medicine, Health Technology, Pharmaceutical industry, Medical device
Locations: US, SILICON VALLEY, NEW YORK, NY, LONDON, LOS ANGELES, CHICAGO, PARIS, TEL AVIV, PENNSYLVANIA, CA, MICHIGAN, MASSACHUSETTS, SEATTLE, WA, PA, PHILADELPHIA, ALASKA, UNITED STATES, NORTH AMERICA, CALIFORNIA, STRYKER
General Health,
Health Technology,
Health,
Medical Devices,
Appendix,
Sale,
Investment,
Research,
Webcast,
Dialysis,
Medicine,
S&M,
Acute,
Marketing,
Bank statement,
GAAP,
G&A,
Video game Outset Medical, Inc. (Nasdaq: OM) (“Outset” or the “Company”), a medical technology company pioneering a first-of-its-kind technology to reduce the cost and complexity of dialysis, today reported financial results for the first quarter ended March 31, 2024.
Key Points:
- Outset Medical, Inc. (Nasdaq: OM) (“Outset” or the “Company”), a medical technology company pioneering a first-of-its-kind technology to reduce the cost and complexity of dialysis, today reported financial results for the first quarter ended March 31, 2024.
- Service and other revenue was $7.7 million, an increase of 36.1% compared to $5.7 million in the first quarter of 2023.
- Product gross profit was $7.8 million, compared to $7.0 million of product gross profit in the first quarter of 2023.
- ET to discuss its first quarter 2024 financial results.
Nursing,
Medical Devices,
FDA,
Health,
Managed Care,
Biotechnology,
Food,
Water,
ICU,
Patient,
Dialysis,
Medicine,
Movement,
Chair,
Medical device Outset has resumed distribution of TabloCart with prefiltration and has product available to ship to customers in the United States.
Key Points:
- Outset has resumed distribution of TabloCart with prefiltration and has product available to ship to customers in the United States.
- "With the FDA's clearance of TabloCart with prefiltration, we have delivered features to the Tablo Hemodialysis System that increase the flexibility for nurses and health systems to serve patients from the ICU to the bedside,” said Leslie Trigg, Chair and CEO of Outset Medical.
- It comes in two versions: one with added storage and another featuring water prefiltration capabilities, meeting diverse clinical needs.
- Key features of TabloCart include:
Versatile prefiltration: With its three customizable prefiltration options, TabloCart is designed to adapt to varying water conditions and also features a booster pump to increase incoming water pressure.
Outset Medical, Inc. (Nasdaq: OM) (“Outset”), a medical technology company pioneering a first-of-its-kind technology to reduce the cost and complexity of dialysis, today announced that members of management will participate at the BofA Securities Health Care conference on Tuesday, May 14, 2024 at 2:20 p.m. Eastern time/11:20 a.m. Pacific time, and at the RBC Capital Markets Global Health Care conference on Wednesday, May 15, 2024 at 1:35 p.m. Eastern time/10:35 a.m. Pacific time.
Key Points:
- Outset Medical, Inc. (Nasdaq: OM) (“Outset”), a medical technology company pioneering a first-of-its-kind technology to reduce the cost and complexity of dialysis, today announced that members of management will participate at the BofA Securities Health Care conference on Tuesday, May 14, 2024 at 2:20 p.m. Eastern time/11:20 a.m. Pacific time, and at the RBC Capital Markets Global Health Care conference on Wednesday, May 15, 2024 at 1:35 p.m. Eastern time/10:35 a.m. Pacific time.
Outset Medical, Inc. (Nasdaq: OM) (“Outset”), a medical technology company pioneering a first-of-its-kind technology to reduce the cost and complexity of dialysis, today announced that it will release financial results for the first quarter of 2024 after the close of trading on Wednesday, May 8, 2024.
Key Points:
- Outset Medical, Inc. (Nasdaq: OM) (“Outset”), a medical technology company pioneering a first-of-its-kind technology to reduce the cost and complexity of dialysis, today announced that it will release financial results for the first quarter of 2024 after the close of trading on Wednesday, May 8, 2024.
- On the same day, at 2:00 p.m. Pacific time (5:00 p.m. Eastern time), Leslie Trigg, Chair and Chief Executive Officer, and Nabeel Ahmed, Chief Financial Officer, will host a conference call to discuss financial and operating results.
- The conference call will begin at 2:00 p.m. Pacific time (5:00 p.m. Eastern time) on Wednesday, May 8, 2024.
- A live and archived webcast of the event will be available on the “Investors” section of the Outset website at https://investors.outsetmedical.com/ .
Retrieved on:
Wednesday, April 17, 2024
Biotechnology,
Health Technology,
Health,
Medical Devices,
Patient,
Caregiver,
Dialysis,
ESKD,
Kidney disease,
Water,
Medicine Under the multi-year agreement, U.S. Renal Care can utilize Outset’s Tablo Hemodialysis System as a home dialysis option throughout the 33 states in which it provides care.
Key Points:
- Under the multi-year agreement, U.S. Renal Care can utilize Outset’s Tablo Hemodialysis System as a home dialysis option throughout the 33 states in which it provides care.
- Patients dialyzing with Tablo report that the system is easy to learn and operate in their home.
- Expanding treatment options in the communities served by U.S. Renal Care will aid in meeting the growing demand of dialysis patients seeking treatment at home.
- "Our collaboration with U.S Renal Care is an important step forward in providing dialysis patients with options for where, when and how they want to dialyze.” said Leslie Trigg, Chair and CEO of Outset Medical.
Medical Devices,
Other Health,
Health,
Health Technology,
Nursing,
Kidney disease,
Nephrology,
Policy,
Kidney failure,
RNS,
American Journal,
ANNA,
Partnership,
Chronic kidney disease,
CKD,
Patient,
Dialysis,
Medicine,
Kidney,
Chair This collaboration underscores Outset’s dedication to supporting the nephrology nursing community and improving patient care in the realm of kidney disease.
Key Points:
- This collaboration underscores Outset’s dedication to supporting the nephrology nursing community and improving patient care in the realm of kidney disease.
- Leslie Trigg, Chair and CEO of Outset, shared her thoughts on the partnership: “We enthusiastically support ANNA’s goal of empowering and educating nephrology nurses who are essential to delivering high-quality care to patients with kidney disease.
- This partnership demonstrates our dedication to enhancing patient outcomes and supporting the vital role of the nephrology nurses who care for them.”
ANNA emphasized the importance of collaboration with industry leaders to advance the nephrology nursing field.
- “Outset Medical’s support, together with our other corporate partners, is important to our mission,” said Michele Kimball, ANNA Executive Director.
Retrieved on:
Wednesday, March 13, 2024
Technology,
Medical Devices,
FDA,
Health Technology,
Professional Services,
Software,
Health,
Data Analytics,
General Health,
Growth,
Medicine,
Mental,
Business,
Patient,
Stryker Corporation,
Gold,
Business development,
Acquisition,
University,
Marketing,
3Com,
Fortune 500,
Dialysis,
Movement,
Audit committee,
Management Outset Medical, Inc. (Nasdaq: OM) (“Outset”), a medical technology company pioneering a first-of-its-kind technology to reduce the cost and complexity of dialysis, today announced the appointment of medical technology veteran Brent D. Lang to its board of directors.
Key Points:
- Outset Medical, Inc. (Nasdaq: OM) (“Outset”), a medical technology company pioneering a first-of-its-kind technology to reduce the cost and complexity of dialysis, today announced the appointment of medical technology veteran Brent D. Lang to its board of directors.
- “Brent brings a wealth of healthcare expertise to the Outset board, including in growing and scaling software-enabled business models, which is well-aligned with our recurring revenue model,” said Leslie Trigg, Chair and Chief Executive Officer.
- “As we welcome Brent, we want to also thank Katie for her service to the Outset board during a period of growth and change following our public offering,” added Ms. Trigg.
- “We wish her well as she begins an exciting new phase of her career journey.”
Mr. Lang will serve on the Audit Committee of the Outset board.
Retrieved on:
Monday, February 26, 2024
Outset Medical, Inc. (Nasdaq: OM) (“Outset”), a medical technology company pioneering a first-of-its-kind technology to reduce the cost and complexity of dialysis, today announced that members of management will present at the 44th annual TD Cowen Health Care conference on Tuesday, March 5, 2024, at 1:30 p.m. Eastern time.
Key Points:
- Outset Medical, Inc. (Nasdaq: OM) (“Outset”), a medical technology company pioneering a first-of-its-kind technology to reduce the cost and complexity of dialysis, today announced that members of management will present at the 44th annual TD Cowen Health Care conference on Tuesday, March 5, 2024, at 1:30 p.m. Eastern time.
Retrieved on:
Wednesday, February 21, 2024
Diabetes,
Health Technology,
Health,
Medical Devices,
Medicine,
Investment,
Marketing,
Dialysis,
Growth,
S&M,
GAAP,
Webcast,
Patient,
G&A,
Appendix,
Bank statement,
Research,
Video game Outset Medical, Inc. (Nasdaq: OM) (“Outset” or the “Company”), a medical technology company pioneering a first-of-its-kind technology to reduce the cost and complexity of dialysis, today reported financial results for the fourth quarter and full year ended December 31, 2023.
Key Points:
- Outset Medical, Inc. (Nasdaq: OM) (“Outset” or the “Company”), a medical technology company pioneering a first-of-its-kind technology to reduce the cost and complexity of dialysis, today reported financial results for the fourth quarter and full year ended December 31, 2023.
- Fourth quarter gross margin reached 25.3% (26.7% on a non-GAAP basis) compared to 16.5% (17.1% on a non-GAAP basis) in the fourth quarter of 2022.
- Product revenue was $22.9 million, representing a decrease of 13.2% compared to $26.4 million in the fourth quarter of 2022.
- Product gross profit was $8.3 million, compared to $4.3 million of product gross profit in the fourth quarter of 2022.
Outset Medical, Inc. (Nasdaq: OM) (“Outset”), a medical technology company pioneering a first-of-its-kind technology to reduce the cost and complexity of dialysis, today announced that it will release financial results for the fourth quarter and full-year 2023 after the close of trading on Wednesday, February 21, 2024.
Key Points:
- Outset Medical, Inc. (Nasdaq: OM) (“Outset”), a medical technology company pioneering a first-of-its-kind technology to reduce the cost and complexity of dialysis, today announced that it will release financial results for the fourth quarter and full-year 2023 after the close of trading on Wednesday, February 21, 2024.
- On the same day, at 2:00 p.m. Pacific time (5:00 p.m. Eastern time), Leslie Trigg, Chair and Chief Executive Officer, and Nabeel Ahmed, Chief Financial Officer, will host a conference call to discuss financial and operating results.
- The conference call will begin at 2:00 p.m. Pacific time (5:00 p.m. Eastern time) on Wednesday, February 21, 2024.
- A live and archived webcast of the event will be available on the “Investors” section of the Outset website at https://investors.outsetmedical.com/ .
